FDA Advisers: Meta-Analysis Does Not Prove That Naproxen Carries Lower CV Risk (FREE)

By Amy Orciari Herman Data from a meta-analysis suggesting that naproxen carries lower cardiovascular risk than other nonsteroidal anti-inflammatory drugs are not reliable, FDA advisers concluded on Tuesday. …
Source: Physician's First Watch current issue - Category: Primary Care Source Type: news